We are very happy to have Ti as a part of our team. She is tirelessly devoted to her work and her clients. Her background in finance and marketing bring a fresh perspective to the office.
GROSSMONT CENTER FOR CLINICAL RESEARCH (GCCR)
La Mesa, California
October 2009 – Present
Clinical Research Coordinator
- To maintain regulatory documentation and to conduct research protocols according to ICH/GCP guidelines.
- To monitor of case report forms for all assigned clinical research trials at GCCR, including QA review prior to monitoring visits.
- Responsible and required as a clinical research coordinator at GCCR to perform the following:
- To have an in-depth knowledge of protocol requirements and good clinical practices as set forth by federal regulations.
- To act as the primary liaison between the investigators, primary care providers, the institutional review board (IRB), and the sponsor and sponsor representatives.
- Along with the investigators, the clinical research coordinator will screen, enroll, and follow study subjects and will ensure that protocol compliance and close monitoring are maintained for all participating research subjects.
- To be responsible for all data and source documentation, adverse experience reporting and maintenance of complete regulatory file.
WaMu INVESTMENTS, INC., A JP MORGAN COMPANY
Irvine, California 2000 – 2009
Lead Discrepancy Commissions Analyst (2005 – 2009)
- Merited repeated promotion from this leading investment Services Company and affiliate of Washington Mutual to processes trade and trail discrepancies and research transactions that did not properly report to the firm’s commission reporting system.
- Position entailed delegating daily work duties, finding resolutions for escalated discrepancy issues, ensuring monthly commission deadlines were met for proper commission payouts to field sales force, producing month end reports for senior management, conducting detailed research and collaborating with other departments in developing a successful commission discrepancy resolution, and tracking and logging all discrepancies.
- Developed a paperless tracking and filing system for discrepancies, assisting in the company’s effort to reduce paper waste and the overall “Go Green” effort.
- Partnered with IT, clearing firm, compliance department, and annuity carriers to develop automated commission reporting for wrap accounts and for annuity business through DTCC.
- Automated reporting improved efficiency in commission reporting to the firm by capturing all commissions that would have been missed with paper commission statements.
Trade Adjustment & Discrepancy Processor (2003 – 2005)
- Advanced on to process mutual fund trade adjustments in a timely and cost efficient manner, providing guidance and training to Financial Advisors and internal staff on departmental policies and procedures governing correction processing, ensuring compliance with existing policies and procedures.
- Scope of responsibility included researching, following up, and responding to internal department personnel and field staff; performing trade away for fixed income trades; ensuring correct processing of fixed income trades were in compliance as outlined by MSRB; and assisting equity trading desk with orders.
- Facilitated transition from Fiserv to National Financial Services clearing firm by switching the mutual fund trade adjustment process from one firm to the other with no delays.
- Efficiently performed fixed income, equity trading, and mutual fund adjustment at the same time as the only professional in the office completing three functions in one department.
Brokerage / Client Service Representative Specialist (2000 – 2003)
- Chosen to work with President Club Financial Advisors, providing personalized operational support in challenging, fast paced call center environment.
- Served as an advocate in cross-department situations to ensure smooth processing of workflow on the Advisors’ behalf.
- Effectively handled escalated calls from internal and external clients, offering working solutions to challenging situations.
- Assisted with operational and administrative functions relating to new accounts, transfers and documentation.
UNIVERSITY OF MARYLAND, ROBERT H. SMITH SCHOOL OF BUSINESS
College Park, Maryland
Bachelor of Science in Marketing
- Series 6, 7, 63 (2000-2009)
- NIH Web-based training course “Protecting Human Research Participants”
- Shipping Infectious Substances (IATA and DOT)
- Good Clinical Practices (on-site training)
- Clinical Research Coordinator (on-site training)
- Rater Experiences:
- Vas Pain Scale
- Patient’s Global Impression of Change (PGIC)
- The Menopause-Specific Quality of Life Questionnaire (MENQOL)
- Pittsburgh Sleep Quality Index (PSQI)
- Vulnerable Elders Survey (VES-13)
- Mini-Mental State Examination (MMSE)
- Perception of Bladder Condition (PPBC)
- Center for Epidemiologic Studies Depression Scale (CES-D)
- Overactive Bladder Questionnaire (OAB-q)
- Overactive Bladder Family Impact Measure (OAB-FIM)
- Overactive Bladder Satisfaction Questionnaire (OAB-S)
CLINCIAL RESEARCH EXPERIENCE
Since October, 2009, I have participated in eleven following clinical studies at Grossmont Center for Clinical Research as Clinical Research Coordinator:
1. An Open-label, Randomized, Parallel Group, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-Dose Oral Contraceptive Containing 0.02 mg XXX and 0.1 mg XXX in a 21 Day Regimen. Agile Therapeutics, Inc.
2. A Multicenter, Randomized, Double-Blinded Study to Evaluate the Efficacy of XXX Compared th Placebo for the Management of Menstrually-Related Migraine Headaches. Teva Women’s Health Research, Inc.
3. A Multi-Center, Double-Blind, Placebo-Controlled Trail of XXX 60 mg Daily in Female OAB Patients on Multiple Concomitant Medications Refractory to Detrol LA 4mg Daily. Allergan.
4. An Open Label Study to Evaluate the Contraceptive Efficacy and Safty of XXX Transdermal Delivery System. Watson Laboratories, Inc.
5. A twenty-eight week, open-label, safety, extension trail of XXX 100 milligrams daily in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder in North America. Boehringer Ingelheim International.
6. A Phase 3B, Multi-Center, Randomized, Double-Blind Study of XXX Injection, 250 mg/ml, Versus Vehicle for the Prevention of Preterm Birth in Women with a Previous Singleton Spontaneous Preterm Delivery. Hologic, Inc.
7. A prospective, Noninterventional Follow-up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received XXX Injection, 250 mg/ml, or Vehicle for the Prevention of Preterm Birth. Hologic, Inc.
8. A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of XXX and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females. Dura Med Research Inc.
9. A Multi-center, Double-Blind, Placebo-Controlled Trial of XXX 60 mg Daily Versus Placebo in Obese (BMI>35Kg/M2) Female OAB Patients. Allergan.
10. A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of XXX in Patients with Iron Deficiency Anemia (IDA). Luitpold Pharmaceuticals, Inc.
11. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of XXX Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Pfizer Inc.